App-Quantinova.ai

Safety of delivery of bortezomib to patients with cardiac AL Amyloidosis: The impact of cardiac monitoring

C. Attwood - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Cardiac arrest

Cyclophosphamide

Real world data of age related cytogenetic abnormality distribution in multiple myeloma patients at diagnosis: single centre experience from the United Kingdom

J. Tam - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

N/A

Renal Reference Ranges for Serum Free Light Chain Ratios: Effectiveness in Excluding Clinically Relevant Plasma Cell Disorders and Reducing Haematology Referrals

H. Laing - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Chronic kidney disease

Lanthanum carbonate

Real world experience of Daratumumab monotherapy as fourth line therapy in relapsed/refractory myeloma

J.B. Taube - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

daratumumab Intravenous

Efficacy and Toxicity of Salvage Second Autologous Stem Cell Transplant In Patients with Relapsed Multiple Myeloma

A. Cooper - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Multiple Myeloma

Lenalidomide

CTDa versus MPT for Multiple Myeloma: Real World Data from The West of Scotland Cancer Network

M. Steel - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Cyclophosphamide

An Algorithm for Blood Pressure Monitoring in Myeloma patients receiving Carfilzomib

J. Boot - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Malignant hypertension

Dexamethasone

Validation of clinical‐grade whole genome sequencing reproduces cytogenetic analysis and identifies mutational landscape in newly‐diagnosed myeloma patients : a pilot study from the 100,000 Genomes Project

O. Lomas - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Methadone hydrochloride

Light chain amyloidosis as a rare complication of solid organ transplantation

F.A. Sharpley - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Lupus

Mycophenolic acid

UK real world experience: european post‐approval safety study (pass) in relapsed/refractory multiple myeloma patients treated with pomalidomide

G. Jackson - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Pomalidomide

Boterzomib‐thalidomide‐dexamethasone induction therapy in myeloma is superior to bortezomib‐cyclophosphamide‐dexamethasone with lower rates of neuropathy: real world data

F. Al-Kaisi - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Peripheral Nervous System

Peripheral neuropathy

Cyclophosphamide

A single centre study to estimate the follow up of patients with monoclonal gammopathy of undetermined significance by community physicians in the UK

I. Ramasamy - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Lympho proliferative disease

N/A

Thromboprophylaxis walk around leads to increased compliance in completing thromboprophylaxis risk assessments and a decrease in Preventable Hospital Acquired Thrombosis

C. Welburn - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Most haematological abnormalities in neonates with Down syndrome are transient but dysplastic myelopoiesis persists throughout early childhood

L. Hanssen - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Acute myelocytic leukemia

N/A

Evaluation of renal dysfunction in a cohort of children with sickle cell disease

A. Kanny - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Sickle cell nephropathy

Hydroxycarbamide

A retrospective review of venous thrombosis in 16‐18 year old patients in a tertiary referral centre over a 5 year period (2013 – 2017)

G. Swallow - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Enoxaparin

Causes, management and outcomes of extreme paediatric thrombocytosis

K. Mckinnon - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Extreme thrombocytosis

N/A

The Effects of Exercise on Oxygen Saturation levels in Paediatric Sickle Cell Disease: A Literature Review

N. Henry - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Sickle cell anemia

SP02

Reversible Reduced Perforin expression in HLH secondary to Salmonella and Rotavirus enteritis

C. Horgan - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Hemophagocytic lymphohistiocytosis

Dexamethasone

Ravulizumab (ALXN1210) versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria: pharmacokinetics and pharmacodynamics observed in two Phase 3 randomized, multicenter studies

R. Peffault De Latour - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Paroxysmal nocturnal hemoglobinuria

Eculizumab

Filters

45280 Abstracts